CATAFLAM
DICLOFENAC POTASSIUM
Approval overview CATAFLAM is listed in Drugs@FDA under application 020142 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DICLOFENAC POTASSIUM Form and strength TABLET;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2021-04-28 00:00:00.
Structured Monograph
Clinical summary
Approval overview CATAFLAM is listed in Drugs@FDA under application 020142 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DICLOFENAC POTASSIUM Form and strength TABLET;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor NOVARTIS Submission history Latest submission status date: 2021-04-28 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.